A
Apellis Pharmaceuticals, Inc. (APLS)
NMS – Real vaqt narxi. Valyuta: USD
41.06
+0.04 (0.10%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
41.06
+0.04 (0.10%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Apellis Pharmaceuticals, Inc., tijorat bosqichidagi biofarmatsevtika kompaniyasi, yuqori ehtiyojlari qoplanmagan kasalliklarni davolash uchun yangi terapevtik birikmalarni kashf qilish, ishlab chiqish va tijoratlashtirishga qaratilgan. Kompaniya paroksismal nokturnal gemoglobinuriyani davolash uchun EMPAVELI; va yoshga bog'liq makula degeneratsiyasi natijasida yuzaga kelgan geografik atrofiya va geografik atrofiya (GA)ni davolash uchun SYFOVREni taklif etadi. Kompaniya, shuningdek, C3-glomerulopatiyani va immunitet kompleksli membranoz proliferativ glomerulonefritni, fokal segmental glomerulosklerozni va kechiktirilgan transplantatsiya funktsiyasini davolash uchun EMPAVELI; va GAni davolash uchun kichik interferentsiya qiluvchi RNK yoki siRNA bo'lgan APL-3007ni ishlab chiqmoqda. Bundan tashqari, kompaniya neonatall Fc retseptoriga, yoki FcRnga yo'naltirilgan davolash usuli bo'lgan APL-9099 uchun preklinik tadqiqotlar olib bormoqda, bu bir martalik dozalash orqali kelajakdagi maqsadli ko'rsatmalarda birinchi o'rinda turadigan gen tahriri usuli bo'lishi mumkin; va o'zining ichki imkoniyatlari va Beam bilan hamkorlik doirasida boshqa dasturlarni ishlab chiqmoqda. Kompaniya pegcetacoplanni ishlab chiqish va tijoratlashtirish bo'yicha Swedish Orphan Biovitrum AB (publ) bilan hamkorlik va litsenziya shartnomasiga ega; va Beam Therapeutics, Inc. bilan komplement tomonidan qo'zg'atilgan kasalliklar uchun yangi davolash usullarini kashf qilish uchun Beam'ning asosiy tahrir texnologiyasidan foydalanishga qaratilgan hamkorlikni amalga oshirmoqda. Apellis Pharmaceuticals, Inc. 2009 yilda tashkil etilgan va shtab-kvartirasi Uolthem, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Caroline R. Baumal M.D. | Chief Medical Officer |
| Dr. Cedric Francois M.D., Ph.D. | Co-Founder, President, CEO & Director |
| Dr. Pascal Deschatelets Ph.D. | Co-Founder & Chief Scientific Officer |
| Mr. Alec Machiels J.D., MBA | Co-Founder & Director |
| Mr. David O. Watson Esq., J.D. | General Counsel & Secretary |
| Mr. James G. Chopas CPA | VP, Corporate Controller & Chief Accounting Officer |
| Mr. Timothy E. Sullivan | CFO & Treasurer |
| Ms. Eva Stroynowski | Head of Investor Relations |
| Ms. Kelley Boucher | Chief People Officer |
| Prof. Peter Hillmen M.D., Ph.D. | Head of Hematology Engagement & Member of PNH Scientific Advisory Board |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | apls-20260331.htm |
| 2026-05-06 | SC 14D9/A | d18695dsc14d9a.htm |
| 2026-05-04 | 8-K | d147392d8k.htm |
| 2026-04-28 | 10-K/A | apls-20251231.htm |
| 2026-04-14 | SC TO-T | d119834dsctot.htm |
| 2026-04-14 | SC 14D9 | d143771dsc14d9.htm |
| 2026-04-07 | SC TO-C | sctoc.htm |
| 2026-04-06 | SC14D9C | d130703dsc14d9c.htm |
| 2026-03-31 | SC14D9C | d133397dsc14d9c.htm |
| 2026-03-02 | 8-K | d115780d8k.htm |